Favrille Cuts IPO Price For Second Consecutive Day; Now At $7-$8 A Share

Underwriters for Favrille Inc., a developer of immunotherapies to treat cancer,
again lowered the estimated price range for its upcoming public offering, this
time to $7 to $8 a share. On Tuesday the IPO price range was cut from $12 to $13
a share to $8 to $9. The company still plans to offer 6 million common shares in
the IPO, which is expected to be priced this week.